Candela's ALEXlazr cleared by FDA:
This article was originally published in Clinica
Candela's ALEXlazr has been cleared by the US FDA for treating pigmented skin lesions. Such lesions are commonly caused by sun exposure and sun damage. The device had previously been cleared for removing tattoos and pigmented dermal lesions. The treatment costs between $100 and $400 per session. The company based in Wayland, Massachusetts, estimates the potential worldwide market to be $2,000 million with over 28 million people in the US alone requiring the treatment.
You may also be interested in...
Can Atlas Biomed unlock Japan's self-care market with its direct-to-consumer DNA and microbiome tests? HBW Insight catches up with the company's co-founder and CEO to discuss this and also how Atlas has been driving its European expansion plans despite coronavirus.
France's ANSES warns women using oral contraceptives not to use a supplement marketed by UK firm Hairburst after linking the product's consumption to two cases of severe acute hepatitis.
A lower first dose boosted the vaccine’s efficacy result, but AstraZeneca has conceded that this has to be proven in a separate trial. In the meantime, the UK government has asked the regulator to assess the vaccine under a special health emergency provision.